Weekly Digest – July 2026 Weekly Digest – July 2026 7 July 2026: China’s NMPA administration accepts Biologics License Application for PADCEV plus Keytruda in Muscle-Invasive Bladder Cancer Astellas have announced that China’s National Medical Products Administration has accepted the […]
Weekly Digest – July 2026 Weekly Digest – July 2026 8 July 2026: Hengrui ADC innovative drug Ruikang Trastuzumab new indication marketing application accepted and included in priority review Hengrui Pharma’s HER2-targeted antibody-drug conjugate Trastuzumab rezetecan has had its new […]
Weekly Digest – July 2026 Weekly Digest – July 2026 6 July 2026: InnoCare Pharma announced that the first patient dosing in the clinical trial of ICP-B208, its novel ADC targeting CDH17 InnoCare Pharma has announced the successful first patient […]
Weekly Digest – July 2026 Weekly Digest – July 2026 06 July 2026: Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients Novartis has agreed to acquire Myricx […]
Weekly Digest – July 2026 Weekly Digest – July 2026 7 July 2026: Biocytogen and Whitehawk Therapeutics enter global collaboration for bispecific antibody ADC development Biocytogen and Whitehawk Therapeutics have entered a global collaboration to develop next-generation bispecific antibody-drug conjugates, […]
Weekly Digest – July 2026 Weekly Digest – July 2026 29 June 2026: Enhertu approved in the EU as the first tumor-agnostic HER2-targeted ADC for previously treated HER2 positive metastatic Solid tumors The European Union has approved Enhertu as the […]
Weekly Digest – July 2026 Weekly Digest – July 2026 29 June 2026: Enhertu approved in the EU as the first tumor-agnostic HER2-targeted ADC for previously treated HER2 positive metastatic Solid tumors The European Union has approved Enhertu as the […]
Weekly Digest – July 2026 Weekly Digest – July 2026 09 July 2026: RyboDyn partners with U.S department of war to advance AI-discovered ADC therapies for Lung cancer RyboDyn received a $1.3 million grant from the U.S. Department of War […]
Weekly Digest – July 2026 Weekly Digest – July 2026 29 June 2026: Enhertu approved in the EU as the first tumor-agnostic HER2-targeted ADC for previously treated HER2 positive metastatic Solid tumors The European Union has approved Enhertu as the […]
Weekly Digest – July 2026 Weekly Digest – July 2026 26 June 2026: Datroway recommended for approval in the EU as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy AstraZeneca and Daiichi Sankyo’s Datroway has […]
